Rosen Law Firm Encourages Aldeyra Therapeutics Investors to Secure Counsel Before Upcoming Deadline

The firm is representing investors in a securities class action lawsuit against the pharmaceutical company.

Apr. 12, 2026 at 6:34am

Got story updates? Submit your updates here. ›

A minimalist studio still life photograph featuring a stack of legal documents, a pen, and a pair of reading glasses arranged on a clean white background, conveying the abstract concepts of corporate strategy, finance, and legal risk.A meticulous legal case file and accessories symbolize the complex financial and regulatory landscape facing public companies.NYC Today

The Rosen Law Firm, a global investor rights law firm, is reminding purchasers of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) securities between November 3, 2023 and March 16, 2026 of the important May 29, 2026 lead plaintiff deadline in the securities class action first filed by the firm. The lawsuit alleges that Aldeyra made false and/or misleading statements about the results of its drug candidate reproxalap during this time period, which caused investors to suffer damages when the true details entered the market.

Why it matters

This case highlights the importance of investors being aware of potential securities fraud and taking action to protect their rights. The Rosen Law Firm has a track record of successfully representing investors in class action lawsuits against public companies.

The details

According to the lawsuit, Aldeyra Therapeutics made false and/or misleading statements and/or failed to disclose that: (1) The results of the reproxalap clinical trials were inconsistent; (2) the inconsistency of the results rendered any purported positive findings from these trials unreliable and not meaningful; and (3) as a result, the company's statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.

  • The class period is from November 3, 2023 to March 16, 2026.
  • The lead plaintiff deadline is May 29, 2026.

The players

Rosen Law Firm

A global investor rights law firm that is representing investors in this securities class action lawsuit against Aldeyra Therapeutics.

Aldeyra Therapeutics, Inc.

A pharmaceutical company that is the defendant in this securities class action lawsuit.

Got photos? Submit your photos here. ›

What they’re saying

“We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition.”

— Phillip Kim, Attorney, Rosen Law Firm

What’s next

Investors have until May 29, 2026 to file as lead plaintiff in the class action lawsuit against Aldeyra Therapeutics.

The takeaway

This case highlights the importance for investors to be vigilant about potential securities fraud and to seek experienced legal counsel to protect their rights. The Rosen Law Firm has a strong track record of success in representing investors in class action lawsuits.